Literature DB >> 3667587

Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain.

M B Robinson1, R D Blakely, R Couto, J T Coyle.   

Abstract

High performance liquid chromatography studies documented the presence of an enzyme activity, N-acetylated alpha-linked acidic dipeptidase (NAALA dipeptidase), in rat brain membranes that cleaves the endogenous brain dipeptide, N-acetyl-L-aspartyl-L-glutamate to N-acetyl-aspartate and glutamate. With ion exchange chromatography, which quantitatively separated [3,4-3H]glutamate from N-acetyl-L-aspartyl-L-[3,4-3H]glutamate, we found that NAALA dipeptidase activity was essentially restricted to nervous tissue and kidney. We characterized NAALA dipeptidase activity in lysed synaptosomal membranes obtained from rat forebrain. Membrane-bound NAALA dipeptidase activity was optimal between pH 6.0 and 7.4 at 37 degrees C. Eadie-Hofstee analysis of kinetic data revealed a rather high apparent affinity for N-acetyl-L-aspartyl-L-glutamate with a Km = 540 nM and a Vmax = 180 nM/mg of protein/min. While NAALA dipeptidase showed a requirement for monovalent anions such as Cl-, the polyvalent anions phosphate and sulfate inhibited enzyme activity 50% at 100 microM and 1 mM, respectively. The divalent metal ion chelators EGTA, EDTA, and o-phenanthroline completely abolished activity, which was partially restored by manganese. Treatment of membranes with 1 mM dithiothreitol abolished NAALA dipeptidase activity. NAALA dipeptidase activity was also sensitive to the aminopeptidase inhibitors bestatin and puromycin, although not to the selective aminopeptidase A inhibitor amastatin. Structure-activity relationships inferred from inhibitor studies suggest that this enzyme shows specificity for N-acetylated alpha-linked acidic dipeptides. NAALA dipeptidase was also potently inhibited by the excitatory amino acid agonist L-quisqualate. Comparison of the properties of NAALA dipeptidase to those of previously characterized enzymes suggests that this is a novel peptidase which may be involved in the synaptic degradation of N-acetyl-L-aspartyl-L-glutamate.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3667587

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  71 in total

Review 1.  NAAG, NMDA receptor and psychosis.

Authors:  Richard Bergeron; Joseph T Coyle
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

2.  2-PMPA, a NAAG peptidase inhibitor, attenuates magnetic resonance BOLD signals in brain of anesthetized mice: evidence of a link between neuron NAAG release and hyperemia.

Authors:  Morris H Baslow; Victor V Dyakin; Karen L Nowak; Basalingappa L Hungund; David N Guilfoyle
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

3.  Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer.

Authors:  Ying Chen; Catherine A Foss; Youngjoo Byun; Sridhar Nimmagadda; Mrudula Pullambhatla; James J Fox; Mark Castanares; Shawn E Lupold; John W Babich; Ronnie C Mease; Martin G Pomper
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

Review 4.  The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research.

Authors:  Benjamin T Ristau; Denise S O'Keefe; Dean J Bacich
Journal:  Urol Oncol       Date:  2013-12-08       Impact factor: 3.498

5.  Local enema treatment to inhibit FOLH1/GCPII as a novel therapy for inflammatory bowel disease.

Authors:  Abhijit A Date; Rana Rais; Taarika Babu; Jairo Ortiz; Pranjali Kanvinde; Ajit G Thomas; Sarah C Zimmermann; Alexandra J Gadiano; Gilad Halpert; Barbara S Slusher; Laura M Ensign
Journal:  J Control Release       Date:  2017-01-31       Impact factor: 9.776

Review 6.  Current use of PSMA-PET in prostate cancer management.

Authors:  Tobias Maurer; Matthias Eiber; Markus Schwaiger; Jürgen E Gschwend
Journal:  Nat Rev Urol       Date:  2016-02-23       Impact factor: 14.432

7.  Substrate specificity of prostate-specific membrane antigen.

Authors:  Marc O Anderson; Lisa Y Wu; Nicholas M Santiago; Jamie M Moser; Jennifer A Rowley; Erin S D Bolstad; Clifford E Berkman
Journal:  Bioorg Med Chem       Date:  2007-08-11       Impact factor: 3.641

8.  The maize d2003, a novel allele of VP8, is required for maize internode elongation.

Authors:  Hongkun Lv; Jun Zheng; Tianyu Wang; Junjie Fu; Junling Huai; Haowei Min; Xiang Zhang; Baohua Tian; Yunsu Shi; Guoying Wang
Journal:  Plant Mol Biol       Date:  2013-11-09       Impact factor: 4.076

Review 9.  The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.

Authors:  James C Evans; Meenakshi Malhotra; John F Cryan; Caitriona M O'Driscoll
Journal:  Br J Pharmacol       Date:  2016-09-23       Impact factor: 8.739

10.  Glutamate carboxypeptidase II is not an amyloid peptide-degrading enzyme.

Authors:  Jesse Alt; Marigo Stathis; Camilo Rojas; Barbara Slusher
Journal:  FASEB J       Date:  2013-03-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.